Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Breast 1

Conditions

Ovarian Neoplasms 5Neoplasms 5Carcinoma, Non-Small-Cell Lung 5Prostatic Neoplasms 4Glioblastoma 4Carcinoma, Renal Cell 4Sarcoma, Alveolar Soft Part 3Sarcoma 3Gliosarcoma 3Fallopian Tube Neoplasms 3Carcinoma, Hepatocellular 3Breast Neoplasms 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Solitary Fibrous Tumor, Pleural 2Mesothelioma, Malignant 2Colorectal Neoplasms 2Carcinosarcoma 2Carcinoma, Ovarian Epithelial 2Brain Neoplasms 2Triple Negative Breast Neoplasms 1Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Salivary Gland Neoplasms 1Rectal Neoplasms 1Pleural Effusion, Malignant 1Neurofibromatosis 1 1Neurofibroma, Plexiform 1Neoplasm Metastasis 1

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × cediranib × Clear all
NCT02498613 2026-05-01

A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
122 enrolled 16 charts
BreastThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡